Acapodene

Biotechs find themselves more coveted  15 Jan 2006
Philadelphia Inquirer, GTx expects to complete the final phase of testing for regulatory approval of its Acapodene prostate-cancer drug by the end of next year. ...

GTx Reports Positive Phase III Trial Interim Analysis Results  Dec 15, 2005
PR Newswire (press release), ...therapy (ADT) experienced highly statistically significant increases in bone mineral density (BMD) after one year of treatment with ACAPODENE(R) (toremifene ...

GTX stock on rise following positive trial results  Dec 15, 2005
Memphis Business Journal, Preliminary findings in a pivotal Phase III clinical study of the drug Acapodene shows that patients being treated for prostate cancer are experiencing up to ...

GTx says drug shown to strengthen bones  Dec 15, 2005
BusinessWeek ...a biotech company specializing in men's health products, said Thursday that data from a late-stage clinical trial showed that its Acapodene treatment increased ...

Daily briefing  Dec 16, 2005
commercialappeal.com (subscription), Memphis bioscience company, GTx said Thursday data from a late-stage clinical trial showed its Acapodene treatment increased bone mineral density in men using ...